SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

RedHill Biopharma Ltd. (RDHL)

RDHL RSS Feed
Add RDHL Price Alert      Hide Sticky   Hide Intro
Moderator: noretreat
Search This Board:
Last Post: 12/4/2016 7:07:03 PM - Followers: 46 - Board type: Free - Posts Today: 0




Market Cap: $60 M
Cash: $14.7 M
Burn-rate : $10 per Year

Shares Out: 6.3 M ( Management holds over 2.6 M shares )
Float: 4 M






Presentation September 2013
http://files.shareholder.com/downloads/AMDA-1C0OBF/2736607566x0x690006/36cdf135-d2c9-4ce8-88d4-df998ade2152/RedHill%20Biopharma%20Presentation%20September%202013.pdf




The Company’s current product pipeline includes:

 

RHB-103 - An oral thin film formulation of rizatriptan, for the treatment of acute migraine, with a U.S. NDA filed and accepted for review by the FDA and a PDUFA date of February 3, 2014.Market Size: Worldwide triptan market for the treatment of migraine exceeds $2 billion*



RHB-102 - A once-daily formulation of ondansetron, for the treatment of chemotherapy and radiotherapy-induced nausea and vomiting, planned for U.S. NDA submission during the first quarter of 2014.Market Size: Worldwide market for serotonin (5-HT3) receptor inhibitors is estimated at $900 million**



RHB-101 - A once-daily formulation of carvedilol, for the treatment of congestive heart failure and high blood pressure, planned to be submitted for a U.S. New Drug Application (NDA) and a Marketing Authorization Application (MAA) in Europe during the second half of 2014.Market Size: Worldwide target market of $500 million**



RHB-105 - A combination therapy for Helicobacter pylori infection, planned to commence a phase II/III trial in the third quarter of 2013.Market Size: U.S. market is estimated at approximately $1-1.5 billion*



RHB-104 - A combination therapy for the treatment of Crohn’s disease, with a phase III clinical study underway.Market Size: Worldwide market exceeded $3.5 billion in 2012



RHB-104 - A combination therapy for the treatment of Multiple Sclerosis (MS), with a Phase IIa proof of concept trial currently underway.Market Size: Worldwide market of over $14 billion*



RHB-104 - A combination therapy for the treatment of Rheumatoid Arthritis, with a planned Phase IIa study.Market Size: Worldwide market of over $20 billion*



RHB-106 - An encapsulated formulation for bowel preparation (laxative) ahead of colonoscopy and other GI procedures.Market Size: Worldwide market is estimated at approximately $1.4 billion*

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RDHL
Current Price
Volume:
Bid Ask Day's Range
SureTrader
RDHL News: Report of Foreign Issuer (6-k) 08:01 AM
RDHL News: RedHill Biopharma to Present at the Jefferies Microbiome Summit 08:00 AM
RDHL News: Statement of Ownership (sc 13g) 11/25/2016 06:07:39 AM
RDHL News: Report of Foreign Issuer (6-k) 11/16/2016 08:01:43 AM
RDHL News: RedHill Biopharma to Present at the German Equity Forum 2016 11/16/2016 08:00:00 AM
News News Alert: Report of Foreign Issuer (6-k) 12/05/2016 08:01:12 AM
PostSubject
#393  Sticky Note Every time I read about the pipeline listed noretreat 10/31/16 09:55:14 AM
#486   Dr. Radi Shahien, MD, principal investigator of the toddski 12/04/16 07:07:03 PM
#485   https://multiplesclerosisnewstoday.com/2016/04/04/experimental-ms-oral-antibioti toddski 12/04/16 02:58:22 PM
#483   yes I've seen the drops to 8. noretreat 12/01/16 02:41:59 PM
#482   another great scottsmith call! TheHound 12/01/16 12:24:22 PM
#481   Look at the 5 year chart on this. toddski 12/01/16 11:03:48 AM
#480   of course. TheHound 12/01/16 08:13:47 AM
#479   could happen. could go to zero! noretreat 12/01/16 07:40:12 AM
#478   investorshub.advfn.com/uimage/uploads/2016/11/30/phgdwCapture.JPG TheHound 11/30/16 05:49:13 PM
#477   death cross imminent. will 10 bucks hold? TheHound 11/30/16 05:04:20 PM
#476   Migdal Insurance & Financial Holdings Ltd now owns toddski 11/27/16 06:08:24 PM
#475   Great board here. Time and price say I Citrati 11/24/16 11:40:16 PM
#474   Pretty sure they have a net present value toddski 11/24/16 07:01:07 PM
#473   One of the better analysis I've seen. Very toddski 11/24/16 08:21:21 AM
#472   yes we will. happy T-day! TheHound 11/22/16 08:01:44 PM
#471   Don't think so, but clearly only time will tell. noretreat 11/22/16 04:27:50 PM
#470   between now and 8 bucks. TheHound 11/22/16 03:22:04 PM
#469   Depends what you call a while. For tykundegex 11/22/16 02:24:55 PM
#468   2013 prices. $8 bottom bounces. is this one TheHound 11/22/16 01:41:45 PM
#467   RedHill Biopharma Announces YELIVA™ (ABC294640) Poster Presentation at noretreat 11/21/16 07:04:48 AM
#466   The SP. toddski 11/20/16 05:43:28 PM
#465   turn around from what? chef911 11/20/16 04:14:44 PM
#464   Ceo sounded lethargic and run down on last toddski 11/19/16 08:00:49 PM
#463   RedHill Biopharma to Present at the German Equity midastouch017 11/16/16 08:21:12 AM
#462   Considering the burn rate I'd say it's a toddski 11/14/16 10:21:36 PM
#461   Clean quarterly report. Good cash on hand but down Amatuer17 11/14/16 07:54:14 AM
#460   RedHill Biopharma Reports 2016 Third Quarter Financial Results midastouch017 11/14/16 07:25:03 AM
#459   This is supposed to be good news? FDA agreed Amatuer17 11/13/16 06:14:58 PM
#458   RedHill Biopharma Reports Positive FDA Type B Meeting midastouch017 11/10/16 08:22:33 AM
#457   There is no doubt that MAP causes CD Avanger 11/07/16 01:30:02 PM
#456   If I were a large institute trying to toddski 11/07/16 11:39:20 AM
#455   Right, all you have to do is research toddski 11/06/16 10:05:00 AM
#454   I'm putting buy orders in from 10.50 down scottsmith 11/06/16 09:10:10 AM
#453   If this treatment works, it will be revolutionary Rob_ 11/06/16 08:36:36 AM
#452   http://journal.frontiersin.org/article/10.3389/fmed.2016.00049/full The evidenc toddski 11/06/16 07:58:53 AM
#451   Short-term stock price predictions are generally not my noretreat 11/04/16 08:18:55 AM
#450   49% chance? TheHound 11/03/16 05:46:43 PM
#449   This is simply a buy and hold. noretreat 11/03/16 04:41:43 PM
#448   would u give this one a > 50% TheHound 11/03/16 01:44:09 PM
#447   Copied from today's PR noretreat 11/03/16 09:25:34 AM
#446   In addition to the other theory I offered noretreat 11/02/16 03:51:24 PM
#445   I'd be willing to bet money that the toddski 11/02/16 01:33:32 PM
#444   Yea...they have 40 million left! scottsmith 11/02/16 12:42:01 PM
#443   They realized they are giving the stock away toddski 11/02/16 12:41:30 PM
#442   Then the company was full of junk for scottsmith 11/02/16 12:40:24 PM
#441   There's your dagger. This is inexplicably the reason toddski 11/02/16 12:35:56 PM
#440   Certainly interesting events transpiring. Citrati 11/02/16 12:34:15 PM
#439   Perhaps this went up in smoke suddenly and noretreat 11/02/16 11:33:37 AM
#438   That makes sense. Rob_ 11/02/16 11:11:11 AM
#437   They were going to issue less than 1 scottsmith 11/02/16 10:47:34 AM
#436   Just so we are on the same page Rob_ 11/02/16 10:44:26 AM
PostSubject